Orlando, Fla.—The use of post-bypass four-factor prothrombin complex concentrate (PCC) decreases transfusions of both red blood cells and plasma in patients undergoing an orthotopic heart transplant who have existing left ventricular assist devices (LVADs), a study has found. The use of the agent, however, did not result in shorter lengths of stay (LOS) in the ICU or hospital, and was not associated with thrombotic complications.
“We see a large number of patients who are undergoing